Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

603087 Gan&Lee Pharmaceuticals.

Closed 08-31 15:00:00

68.93

-1.45

-2.06%

High69.99	Low67.98	Vol6.84M
Open69.95	D1 Closing70.38	Amplitude2.86%
Mkt Cap41.15B	Tradable Cap38.67B	Total Shares597.00M
T/O471.00M	T/O Rate1.22%	Tradable Shares561.00M
P/B3.52	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"Gan&Lee Pharmaceuticals.","latestPrice":68.93,"timestamp":1788159601000,"preClose":70.38,"halted":0,"volume":6836729,"delay":0,"changeRate":-0.0206,"floatShares":561000000,"shares":597000000,"eps":1.9244,"marketStatus":"Closed","change":-1.45,"latestTime":"08-31 15:00:00","open":69.95,"high":69.99,"low":67.98,"amount":471000000,"amplitude":0.0286,"askPrice":68.93,"askSize":89,"bidPrice":68.92,"bidSize":55,"shortable":0,"etf":0,"ttmEps":1.9244,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"adjPreClose":70.38,"symbolType":"stock","openAndCloseTimeList":[[1788139800000,1788147000000],[1788152400000,1788159600000]],"highLimit":77.42,"lowLimit":63.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597432169,"isCdr":false,"pbRate":3.52,"roa":"--","peRate":35.818957,"roe":"5.15%","epsLYR":1.93,"committee":-0.158879,"marketValue":41181000000,"turnoverRate":0.0122,"status":1,"floatMarketCap":38698000000},"requestUrl":"/m/hq/s/603087/wiki","defaultTab":"wiki","newsList":[{"id":"2662799305","title":"Gan & Lee Pharma's H1 Profit Rises 1%, Revenue Climbs 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662799305","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662799305?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:44","pubTimestamp":1787733886,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals'  net profit attributable to shareholders in the first half rose 1% to 609.8 million yuan from 603.7 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share grew year on year to 1.03 yuan from 1.02 yuan.Operating revenue increased 7.6% to 2.22 billion yuan from 2.07 billion yuan in the previous year.The Chinese pharmaceutical company's shares closed 4% higher.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FCA","BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778083","title":"Gan & Lee Pharmaceuticals H1 Net Profit up 1.01% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778083","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662778083?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:14","pubTimestamp":1787649258,"startTime":"0","endTime":"0","summary":"BRIEF-Gan & Lee Pharmaceuticals H1 Net Profit Up 1.01% Y/YAug 25 (Reuters)-Gan & Lee Pharmaceuticals603087.SS:H1 NET PROFIT UP 1.01% Y/YSource textFurther company coverage:603087.SS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL4N44M0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662784146","title":"Gan & Lee Pharmaceuticals Subsidiary Secures China Clinical Trial Nod for Weight Loss Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662784146","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662784146?lang=en_us&edition=fundamental","pubTime":"2026-08-25 15:58","pubTimestamp":1787644738,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals'  Shandong subsidiary received clinical trial approval from China's National Medical Products Administration for its investigational GZC8072 drug for weight control, according to a Tuesday filing with the Shanghai bourse.The tablets use the company's peptide technology platforms for a once-weekly regimen, the diabetes drug maker said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150959093","title":"Executive Team Sells Shares at Gan & Lee Pharmaceuticals Amid Concerns Over Earnings Quality and Growth Ceiling","url":"https://stock-news.laohu8.com/highlight/detail?id=1150959093","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150959093?lang=en_us&edition=fundamental","pubTime":"2026-08-14 12:11","pubTimestamp":1786680695,"startTime":"0","endTime":"0","summary":"Recently, Gan & Lee Pharmaceuticals announced a shareholder reduction plan involving seven key executives, including Chairman Chen Wei, Directors Song Weiqiang and Du Kai, as well as senior managers...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK4590","BK4144","JDOC","GLP","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160122906","title":"Pharmaceutical Rally Continues: Gan&Lee Pharmaceuticals Hits Limit-Up, Beone Medicines Logs 6-Day Winning Streak; Huabao Funds' HK Medical and Innovation Drug ETFs Rise for Third Consecutive Session","url":"https://stock-news.laohu8.com/highlight/detail?id=1160122906","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160122906?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447849,"startTime":"0","endTime":"0","summary":"On August 11, A-shares and Hong Kong stocks experienced a significant pullback, with healthcare assets broadly peaking and then retreating due to overall market conditions. However, the innovative...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU1303224171.USD","603087","159316","LU0228659784.USD","LU1719994722.HKD","BK1161","159828","BK4585","LU1251922891.USD","688235","LU0588546209.SGD","FLHK","LU0307460666.USD","BK0239","BK1583","ONC","06160","LU0828237510.HKD","LU2328871848.SGD","BK1500","BK1588","BK4588","BK4139","BK4526","KURE","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658967961","title":"Gan & Lee Pharmaceuticals Grants Menarini Licensing Rights to Develop Diabetes Drug in Europe; Shares Jump 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658967961","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658967961?lang=en_us&edition=fundamental","pubTime":"2026-08-11 14:49","pubTimestamp":1786430972,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  granted Italian drug manufacturer Menarini licensing rights for the Chinese company's bofanglutide drug for type 2 diabetes and obesity, according to a Tuesday filing with the Shanghai Stock Exchange.The license deal will allow Menarini to develop and commercialize the drug across 39 European countries and regions, including the 27 members of the EU, as well as the UK, Switzerland, Norway, Iceland, Liechtenstein, and the Balkans.Menarini will pay a non-refundable, initial payment of 62 million euros to Gan & Lee, as well as research, market launch, and sales milestone payments of up to 664 million euros, the Chinese diabetes drug company said.Shares surged 10% during afternoon trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188990255","title":"Gan\\u0026Lee Pharmaceuticals Signs Licensing Agreement with Menarini for Bofang Liraglutide Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1188990255","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188990255?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:00","pubTimestamp":1786356019,"startTime":"0","endTime":"0","summary":"Gan\\u0026Lee Pharmaceuticals (603087.SH) has announced the signing of an exclusive licensing agreement with Menarini. The deal grants Menarini the rights to pursue marketing registration and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651194518","title":"Gan & Lee Pharmaceuticals Gets China Nod for Breast Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651194518","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651194518?lang=en_us&edition=fundamental","pubTime":"2026-07-13 16:21","pubTimestamp":1783930900,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received clinical trial approval from China's drug regulator for GLR2038 tablets to treat advanced breast cancer.The drug, developed on the company's proprietary PROTAC platform, will proceed to monotherapy trials, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650025099","title":"Gan & Lee Pharmaceuticals Secures Honduras Approval for Diabetes Drug; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650025099","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650025099?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:16","pubTimestamp":1783664180,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals  received drug registration approval in Honduras for its insulin glargine injection, Vitaglar.The drug is a long-acting basal insulin for the treatment of diabetes, according to a Friday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 6% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162731774","title":"Gan&Lee Pharmaceuticals Secures Honduran Regulatory Approval for Its Insulin Glargine Prefilled Pen","url":"https://stock-news.laohu8.com/highlight/detail?id=1162731774","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162731774?lang=en_us&edition=fundamental","pubTime":"2026-07-09 17:50","pubTimestamp":1783590629,"startTime":"0","endTime":"0","summary":"Gan&Lee Pharmaceuticals. (ASX: 603087) has announced that it has received a drug registration approval from the Honduran National Drug Administration for its insulin glargine injection (prefilled...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647437553","title":"Gan & Lee Pharmaceuticals Gets Honduras Approval for Insulin Jab","url":"https://stock-news.laohu8.com/highlight/detail?id=2647437553","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647437553?lang=en_us&edition=fundamental","pubTime":"2026-06-29 18:54","pubTimestamp":1782730460,"startTime":"0","endTime":"0","summary":"Honduran authorities approved Gan & Lee Pharmaceuticals' (SHA:603087) insulin glargine injection for diabetes, according to a Monday filing with the Shanghai bourse.The drug is said to have a hypoglycemic effect lasting 24 hours, the company said in its filing.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142698666","title":"Gan & Lee Pharmaceuticals Secures Registration Approval for Insulin Glargine Injection in Honduras","url":"https://stock-news.laohu8.com/highlight/detail?id=1142698666","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142698666?lang=en_us&edition=fundamental","pubTime":"2026-06-26 18:16","pubTimestamp":1782469012,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (SHSE: 603087) has announced that it recently received a drug registration approval for its Insulin Glargine Injection from the National Pharmaceutical Regulatory Authority...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152271526","title":"Gan & Lee Pharmaceuticals Seizes a Niche Opportunity in the Insulin Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1152271526","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152271526?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:21","pubTimestamp":1782224477,"startTime":"0","endTime":"0","summary":"The recent market rotation has seen the spotlight shift from AI to the pharmaceutical sector, with innovative drug stocks capturing investor attention. Some have quipped that healthcare stocks only...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134844537","title":"Gan & Lee Pharmaceuticals Secures UAE Drug Registration for Insulin Glargine Pre-filled Pen","url":"https://stock-news.laohu8.com/highlight/detail?id=1134844537","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134844537?lang=en_us&edition=fundamental","pubTime":"2026-06-18 17:04","pubTimestamp":1781773475,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals Co., Ltd. (SHSE: 603087) has announced that its wholly-owned European subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, has recently received a drug registration approval...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642600902","title":"Gan & Lee Pharmaceuticals - Once-Weekly Insulin Ludefen Shows Favorable Safety Profile With No Severe Hypoglycemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2642600902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642600902?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:01","pubTimestamp":1781265672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42J154:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260099","title":"Gan & Lee Pharmaceuticals - Insulin Ludefen (Gzr4) Meets Primary Endpoint in Phase Iii Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260099","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260099?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:01","pubTimestamp":1781265672,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42J154:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102374961","title":"Gan & Lee Pharmaceuticals Unveils Restricted Stock Incentive Plan for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1102374961","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102374961?lang=en_us&edition=fundamental","pubTime":"2026-06-10 20:28","pubTimestamp":1781094500,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals. (ASX: 603087) has announced a draft proposal for a 2026 restricted stock incentive plan.The plan proposes to grant a total of 630,000 restricted shares to the incentive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123200243","title":"Gan & Lee Pharmaceuticals Subsidiary Secures ANVISA Sterile Preparation GMP Certification in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=1123200243","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123200243?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:20","pubTimestamp":1779787221,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) has announced that its subsidiary, Gan & Lee Pharmaceuticals Brazil Trading and Pharmaceutical Import Co., Ltd., recently received a Good Manufacturing Practice...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159100","BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199496588","title":"Gan & Lee Pharmaceuticals Receives European Commission Approval for Insulin Lispro Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1199496588","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199496588?lang=en_us&edition=fundamental","pubTime":"2026-05-14 16:34","pubTimestamp":1778747669,"startTime":"0","endTime":"0","summary":"Gan & Lee Pharmaceuticals (603087.SH) announced that the company and its European wholly-owned subsidiary, Gan & Lee Pharmaceuticals Europe GmbH, have recently received notification from the European...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPOS","BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633411372","title":"Gan & Lee Pharmaceuticals Gets Nod to Market Dazparda in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2633411372","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633411372?lang=en_us&edition=fundamental","pubTime":"2026-05-07 16:04","pubTimestamp":1778141042,"startTime":"0","endTime":"0","summary":"The European Commission granted Gan & Lee Pharmaceuticals  marketing authorization for insulin aspart injection Dazparda, according to a Shanghai bourse filing on Thursday.The Chinese pharmaceutical company's unit, Gan & Lee Pharmaceuticals Europe, is the authorized marketer of the product in Europe.The company's shares rose 1% at the close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788164938362,"stockEarnings":[{"period":"1week","weight":0.0285},{"period":"1month","weight":0.0333},{"period":"3month","weight":0.3462},{"period":"6month","weight":0.0873},{"period":"1year","weight":0.0035},{"period":"ytd","weight":0.0538}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"75587人(较上一季度减少7.78%)","perCapita":"7427股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59743万元","survey":"　　甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gan&Lee Pharmaceuticals.,603087,Gan&Lee Pharmaceuticals.股票,Gan&Lee Pharmaceuticals.股票老虎,Gan&Lee Pharmaceuticals.股票老虎国际,Gan&Lee Pharmaceuticals.行情,Gan&Lee Pharmaceuticals.股票行情,Gan&Lee Pharmaceuticals.股价,Gan&Lee Pharmaceuticals.股市,Gan&Lee Pharmaceuticals.股票价格,Gan&Lee Pharmaceuticals.股票交易,Gan&Lee Pharmaceuticals.股票购买,Gan&Lee Pharmaceuticals.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gan&Lee Pharmaceuticals.(603087),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gan&Lee Pharmaceuticals.(603087) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction